AI assistant
INVION LIMITED — Share Issue/Capital Change 2020
Dec 3, 2020
65148_rns_2020-12-03_d5fb5e3c-413a-4132-be3e-24796c935c57.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
==> picture [146 x 53] intentionally omitted <==
ASX Announcement
4 December 2020
Lapse of Unlisted Share Options
Invion Limited (ASX.IVX) wishes to advise that the following unlisted share options have lapsed.
| Lapsed Options | Exercise Price | Expiry Date |
|---|---|---|
| 8,177,284 | $0.0300 | 12/02/2023 |
| 5,000 | $0.0175 | 18/11/2020 |
The number of options on hand following the lapse of the above options are as follows:
| *ASX security code and description | *Total number of +securities onissue |
|---|---|
| IVXAT OPT @ $0.03 Exp 12/02/2023IVXAU OPT @ $0.02 Exp 30/10/2023IVXAV OPT @ $0.0172 Exp 31/08/2024IVXAAA OPT @ $0.02 Exp 01/07/2024IVXAY OPT @ $0.0177 Exp 22/10/2024IVXAW OPT @ $0.00 Exp 31/10/2024IVXAZ OPT @ $0.0106 Exp 31/10/2024 | 199,434,8802,725,76120,443,21115,928,57020,443,2115,689,6232,725,762 |
Media enquires
Investor enquiries Media enquires Thian Chew (Chairman & CEO) Brendon Lau T: +61 3 9692 7222 T: +61 409 341 613 E: [email protected] E: [email protected]
Invion Limited ABN 76 094 730 417
Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 9692 7222 W: www.inviongroup.com
==> picture [146 x 53] intentionally omitted <==
About Invion
Invion is a life-science company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the PhotosoftTM technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact [email protected].
About Photodynamic Therapy (PDT)
Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.
Invion Limited ABN 76 094 730 417
Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 9692 7222 W: www.inviongroup.com